Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

The QualityStocks Daily Newsletter would like to spotlight Quantum BioPharma Ltd. (NASDAQ: QNTM) (OTC: QNTM).

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) , a biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders, announced that Kingswood Capital Partners has initiated coverage with a BUY rating and a US$45 price target. The valuation, based on discounted cash flow, assumes successful Phase 2 and 3 trials of lead candidate Lucid-MS between 2026 and 2028 and a commercial launch in 2029. The report, led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, is unpaid and was prepared independently without consideration from Quantum BioPharma.

To view the full press release, visit https://ibn.fm/S27oE

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd™, a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

The company’s vision is to revolutionize healthcare solutions for underserved markets, guided by a mission to enhance lives through science and innovation. By leveraging its expertise in medicinal chemistry and product commercialization through joint ventures, Quantum BioPharma aims to make significant strides in its targeted sectors.

Quantum BioPharma is headquartered in Toronto, Canada.

Lucid-MS

Lucid-MS is Quantum BioPharma’s flagship therapeutic candidate for the treatment of multiple sclerosis (MS). This new chemical entity (NCE) is the result of over 14 years of preclinical research and has demonstrated the potential to stop and even reverse myelin degradation, a known cause of MS. Unlike current treatments, Lucid-MS offers a neuroprotective approach without immunosuppression, addressing a critical unmet need in the MS market.

With nearly one million people in the U.S. living with MS and over 2.8 million cases globally, Lucid-MS targets a vast market with significant demand for better treatment options. In December 2024, Quantum BioPharma announced promising news from its ongoing phase 1 trial of Lucid-MS – a safety review committee recommended starting the dosing of the trial’s second cohort. Lucid-MS represents a transformative opportunity in the treatment of demyelinating diseases. The company is leveraging an expedited regulatory pathway to reach patients faster and has indicated that a phase 2 clinical trial is likely on the horizon.

Celly Nutrition and unbuzzd™

Quantum BioPharma’s product portfolio is anchored by unbuzzd, a dietary supplement in both powder stick and 12 oz. RTD beverage formats, developed by Quantum and licensed to Celly Nutrition, designed to accelerate alcohol metabolism and restore mental alertness within minutes. This clinically tested first-to-market solution utilizes a proprietary blend of extracts, vitamins, and minerals to reduce blood alcohol concentration (BAC) and improve cognitive function post-alcohol consumption. Launched in August 2024, unbuzzd is part of a growing consumer market for hangover remedies, but unique with its effectiveness in rapidly reducing BAC.

The product’s innovative formulation sets it apart as the only clinically tested, effective dietary supplement beverage targeting alcohol detoxification. Its multi-channel distribution strategy includes direct-to-consumer sales through e-commerce platforms, retail partnerships, and on-premise marketing initiatives. Quantum BioPharma’s focus on consumer education and strategic partnerships positions unbuzzd for significant growth within the expanding hangover remedy market.

Market Opportunity

Quantum BioPharma operates in sectors with significant growth potential. The global market for hangover remedies was valued at $2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8%, reaching $6.2 billion by 2030, according to Grand View Research. This growth is fueled by increasing consumer demand for effective alcohol detoxification solutions and rising awareness of products like unbuzzd.

Similarly, the global multiple sclerosis market is projected to grow from $28.2 billion in 2022 to $41 billion by 2033, driven by advancements in treatment options and an increasing prevalence of MS cases worldwide.

Quantum BioPharma’s dual focus on consumer health products and high-value therapeutics uniquely positions it to capitalize on these opportunities. Its strategic investments and innovative R&D pipeline provide a competitive edge in addressing unmet needs in both markets.

Leadership Team

Zeeshan Saeed, CEO and Co-Founder of Quantum BioPharma, has extensive experience in international capital markets and a proven track record of successfully assisting startups in raising initial funding. Under his leadership, Quantum BioPharma has developed a robust portfolio of innovative products and strategic investments.

Gerry David, Director and Co-Chair of Celly Nutrition, brings decades of experience in consumer-packaged goods (CPG) and is best known for his tenure as CEO of Celsius Holdings. During his leadership, he increased the company’s valuation by 35-fold, surpassing $9 billion. His expertise in scaling product distribution programs has been instrumental to Quantum BioPharma’s strategic initiatives.

John Duffy, CEO of Celly Nutrition, has over two decades of leadership experience in the Coca-Cola system, where he served as Vice President of National Sales. His expertise in customer management and sales strategy is driving the success of unbuzzd’s market rollout.

Quantum BioPharma Ltd. (NASDAQ: QNTM), closed Wednesday's trading session at $16.17, up 27.4232%, on 482,589 volume. The average volume for the last 3 months is 173,102 and the stock's 52-week low/high is $2.7/$38.25.

Recent News

• Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) - InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
• InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) Provides Corporate Update
• InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) to Seek Shareholder Approval for $600K Private Placement 

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

Wearable Devices (NASDAQ: WLDS, WLDSW) , a technology growth company specializing in artificial intelligence-powered touchless sensing wearables, announced financial results for the six months ended June 30, 2025, highlighted by the commercial launch of its Mudra Link wristband. The company reported strong revenue momentum from both Mudra Link and Mudra Band, alongside a significantly reduced net loss compared to last year. Management said the results underscore growing demand for intuitive, touchless interfaces and position Wearable Devices as a leader in the global wearables market. CEO Asher Dahan noted continued investment in R&D, marketing and operations, as well as strategic opportunities spanning consumer electronics, military applications and health analytics, with potential to unlock multi-million-dollar B2B contracts.

To view the full press release, visit https://ibn.fm/y6sSD

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Wednesday's trading session at $5.18, up 407.8431%, on 290,202,930 volume. The average volume for the last 3 months is 13,590,657 and the stock's 52-week low/high is $1/$27.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Reports First-Half 2025 Results, Marks Commercial Debut of Mudra Link
• TechMediaBreaks - Why Wearable Devices Ltd. (NASDAQ: WLDS) Is 'One to Watch'
• Wearable Devices Ltd. (NASDAQ: WLDS): How Neural Interface Patents Are Securing the Future of Touchless Control

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Massimo Group (NASDAQ: MAMO) , a manufacturer and distributor of powersports vehicles, announced the completion of a comprehensive sales and product training session with the largest farm and ranch retailer in the United States. Massimo products are currently available in more than 1,200 of the retailer's locations, with expansion into 100-plus additional stores planned. Discussions also included broadening the product lineup to feature the new T-Boss 900L UTV, expanded ATV models and growing go-kart offerings. CEO David Shan said the partnership is a cornerstone of Massimo's growth strategy, helping the company reach families nationwide. Massimo continues to invest in product development and retail partnerships to drive growth through 2026 and beyond.

To view the full press release, visit https://ibn.fm/nHLWk

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Wednesday's trading session at $2.6, up 1.5625%, on 13,861 volume. The average volume for the last 3 months is 21,899 and the stock's 52-week low/high is $1.839/$4.6599.

Recent News

• Massimo Group (NASDAQ: MAMO) - Porsche Shelves Plans to Make its Own EV Batteries Over Cost Concerns
• InvestorNewsBreaks - Massimo Group (NASDAQ: MAMO) Showcases New Products and Growth Strategy at Mid-States 2025 Rendezvous
• Massimo Group (NASDAQ: MAMO) Accelerates Golf Cart Market Reach with Vietnam Partnership

GlobalTech Corp. (OTC: GLTK)

The QualityStocks Daily Newsletter would like to spotlight GlobalTech Corp. (OTC: GLTK).

GlobalTech balances internal innovation with strategic acquisitions in AI, big data, and digital infrastructure

Q2 2025 revenue increased 23.3% year-over-year to $5.63 million, driven by telecom services growth

Company advancing capital markets profile with private placement and strategic advisor appointment, supporting uplisting ambitions

Technology at the Core of Business Growth

Technology has become the defining force behind business scalability, value, and social impact in the modern economy. As industries embrace the Fourth Industrial Revolution, platforms built on artificial intelligence ("AI"), big data, and digital infrastructure are reshaping global value chains. Companies that combine operational technology with access to capital markets are uniquely positioned to accelerate transformation and unlock long-term growth.

GlobalTech (OTCID: GLTK), a U.S.-based technology holding company, has emerged as one such entity. With operations spanning North America, Europe, the Middle East, and South Asia, the company aggregates and accelerates businesses across exponential technologies while delivering scalable solutions to both enterprises and consumers.

GlobalTech Corp. (OTC: GLTK) is a U.S.-based technology holding company specializing in artificial intelligence (AI), big data, and digital infrastructure. Advancing toward a Nasdaq listing, the company balances internal innovation with strategic acquisitions to accelerate growth and long-term value creation.

GlobalTech’s diversified portfolio spans AI-powered solutions for enterprise productivity, e-commerce, retail, digital lending, compliance, and other high-growth domains. Flagship platforms include ThrivoAI, Cadnz, Baseball Blitz, Talina, ProtoEd, BillCare, Giftio, and EntityScan. The company also holds a majority stake in WorldCall Telecom Ltd., extending its telecommunications presence in Pakistan and supporting infrastructure-led value creation.

To strengthen market reach, GlobalTech continues to evaluate technology-centric acquisitions while also expanding through strategic regional alliances. Its partnership with significant regional players like Omantel anchors growth in the Middle East, a key gateway market. At the same time, the company’s Center of Excellence (CoE) and #GTCTalks knowledge platform position it as a thought leader in emerging technologies.

Supported by a seasoned leadership team and a disciplined execution model, GlobalTech is building sustainable momentum across global AI and big data markets, with the governance, innovation, and agility required to capture outsized opportunities in the digital economy.

GlobalTech Corp. (OTC: GLTK), closed Wednesday's trading session at $2.1099, up 0.4714286%, on 1,960 volume. The average volume for the last 3 months is 730 and the stock's 52-week low/high is $0.75/$3.4.

Recent News

• GlobalTech Corp. (OTC: GLTK) - https://www.investorbrandnetwork.com/market-research/?qmtab=detailedquotetabchartnews_qmsymbol=GLTK&qmodStoryID=7100609100667835
• AINewsBreaks - GlobalTech Corp. (OTC: GLTK) Closes $1.4 Million Convertible Note Private Placement
• TechMediaBreaks - Why GlobalTech Corp. (GLTK) Is 'One to Watch'

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Modern golfers rely on a range of innovations to enhance every aspect of their performance.

Newton Golf Company has embraced the ideals of innovation and high tech, applying them directly to the design and production of its golf equipment.

In addition to equipment, Newton Golf integrates technology into its customer experience, training and education services.

Golf is evolving faster than ever, thanks to advancements in technology that are reshaping how players train, compete and enjoy the sport. Newton Golf Company (NASDAQ: NWTG) is at the forefront of this transformation, blending innovative technology with traditional craftsmanship to produce high-performance golf equipment. The company's focus on incorporating precision engineering, data-driven design and advanced materials into its clubs and accessories is helping golfers of all skill levels improve their game and experience the sport in new ways.

Newton Golf Company (NASDAQ: NWTG) , a technology-forward golf company delivering performance-driven innovations through physics-based engineering, announced that Addison Kloch, one of Southern California's top junior golfers, has joined the Newton Golf team as an affiliated athlete. A member of the Class of 2026 from Agoura Hills, California, Kloch recently announced her verbal commitment to play Division I golf at California State University, Fullerton. Her achievements include three-time Marmonte League First Team honors, a 2024 All-Ventura County First Team selection, recognition as California Junior Player of the Year in the Championship Girls Division, and an AJGA Top-300 national ranking. Kloch has credited Newton Motion shafts for adding stability and consistency to her game, further highlighting the company's role in supporting her rapid ascent in the sport.

To view the full press release, visit https://ibn.fm/OTkN7

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Wednesday's trading session at $1.94, up 4.3011%, on 268,386 volume. The average volume for the last 3 months is 148,126 and the stock's 52-week low/high is $1.35/$119.1.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Signs Junior Golf Standout Addison Kloch as Affiliated Athlete
• Newton Golf Company Inc. (NASDAQ: NWTG) Integrates Advanced Technology to Elevate Golf Performance
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Named Official Partner of World Long Drive 2025 Season

PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight PowerBank Corporation (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) , a leader in North American energy infrastructure development and asset ownership, announced it has secured all required municipal approvals for two community solar projects on industrial brownfield sites in Skaneateles, New York, located in Onondaga County. With variances, site plan approval and a special use permit in place, the projects will now pursue approval from the New York Department of Environmental Conservation ahead of construction. Once operational, the projects will deliver clean energy to the local grid, allowing renters and homeowners to subscribe and earn bill credits without installing panels on their properties. Supported by PowerBank's track record of more than 100 MW of completed projects and a 1 GW development pipeline, the Skaneateles projects will advance New York's Climate Leadership and Community Protection Act goal of 6 GW of solar capacity by 2025.

To view the full press release, visit https://ibn.fm/Fe8IF

PowerBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. PowerBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, PowerBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, PowerBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

PowerBank has offices in Toronto, Ontario and New York.

Projects

PowerBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, PowerBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of PowerBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, PowerBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

PowerBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

PowerBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance PowerBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, PowerBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of PowerBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of PowerBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive PowerBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by PowerBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

PowerBank Corporation (NASDAQ: SUUN), closed Wednesday's trading session at $1.87, up 1.6304%, on 167,598 volume. The average volume for the last 3 months is 507,044 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

• PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) - ESGBreaks - PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Updates on Skaneateles Community Solar Projects
• Amazon to Power its New Zealand Data Centers with Renewable Energy
• Most New Energy Capacity in H1 in the US Was Renewable

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

Vision Marine Technologies (NASDAQ: VMAR) , a pioneer in electric marine propulsion, announced the advancement of its Electric Representative Training Program across Nautical Ventures' Florida dealership network. The program has completed its first phase with the training of Electric Representatives at key locations, enabling customers to receive expert guidance on the company's proprietary E-Motion(TM) 180E, the first certified 180 HP continuous electric outboard. Vision Marine has already delivered two E-Motion 180E-equipped boats, with more integrations scheduled for delivery in the coming weeks and is now launching on-water training sessions and customer demonstrations. CEO Alexandre Mongeon said the program combines education with real-world experience to support adoption, while recent deliveries confirm active production. Multiple Vision electric boats are now in stock at Nautical Ventures' east and west coast showrooms for immediate delivery.

To view the full press release, visit https://ibn.fm/b5yPE

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Wednesday's trading session at $1.38, up 6.9767%, on 553,308 volume. The average volume for the last 3 months is 1,375,227 and the stock's 52-week low/high is $1.25/$267.3.

Recent News

• Vision Marine Technologies Inc. (NASDAQ: VMAR) - TinyGemsBreaks - Vision Marine Technologies Inc. (NASDAQ: VMAR) Expands Electric Training Program at Nautical Ventures Dealerships
• Vision Marine Technologies Inc. (NASDAQ: VMAR) Strengthens Electric Watercraft Position with Seabob Partnership
• InvestorNewsBreaks - Vision Marine Technologies Inc. (NASDAQ: VMAR) Launches Inventory Auction to Support Operational Optimization and Integration Expansion

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

The system's design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine.

HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year.

For decades, the traditional 12-lead electrocardiogram ("ECG") has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart's electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart's electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Wednesday's trading session at $1.37, up 3.0075%, on 64,667 volume. The average volume for the last 3 months is 116,566 and the stock's 52-week low/high is $0.9101/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
• InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias 
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) to Present at Three September Investor Conferences

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline Holdings (NASDAQ: BLNE), a digital mortgage platform, was highlighted in a Sept. 9, 2025 Streetwise Reports article by John Newell of John Newell & Associates, which emphasized the company's elimination of $7 million in debt and expansion of its proprietary AI sales agent "Bob." The report noted that Beeline is guiding toward profitability by early 2026 and that shares recently broke through their first technical target of $2.20, "confirming momentum and opening the door for higher levels."

According to Streetwise Reports , Beeline enters Q4 with 19.6 million shares outstanding, a market cap of about $49 million, and zero debt. The article pointed to the company's new fractional equity platform and leadership team's fintech track record as additional growth drivers. Ladenburg Thalmann maintained its Buy rating with a $4.50 price target, aligning with technical upside projections.

To view the full report, visit https://ibn.fm/6Mwrd

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Wednesday's trading session at $2.14, off by 17.6923%, on 3,224,078 volume. The average volume for the last 3 months is 2,215,769 and the stock's 52-week low/high is $0.6202/$10.5.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - TechMediaBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Featured in Streetwise Reports for Clearing Debt and Expanding AI Platform
• AINewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) to Present at Centurion One Capital Summit in Bahamas 
• InvestorNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Insider Buying Led by COO's 100,000-Share Purchase

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Oncotelic Therapeutics (OTCQB: OTLC) , a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for cancer and underserved diseases, announced it has selected IBN to spearhead its corporate communications. Oncotelic is advancing therapies for difficult-to-treat and rare conditions, including pediatric cancers and aggressive solid tumors, with its lead candidate OT-101 currently in a Phase 3 trial for pancreatic ductal adenocarcinoma. Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane(R), the company is building a multi-asset pipeline supported by proprietary AI platform PDAOAI and a 45% stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited capable of supporting regulatory filings for up to 20 drug candidates.

To view the full press release, visit https://ibn.fm/PTeNg

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Wednesday's trading session at $0.0475, up 1.5825%, on 43,181 volume. The average volume for the last 3 months is 39,830 and the stock's 52-week low/high is $0.017/$0.07.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications
• BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu's Impact and Clinical Pipeline Progress
• Oncotelic Therapeutics Inc. (OTLC) Is 'One to Watch'

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing

AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety

Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales

The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important.

Market Confidence Meets Innovation

Nutriband (NASDAQ: NTRB) recently secured $5.3 million through warrant exercises at $6.43 per share, a voluntary move by investors that underscores faith in the company's trajectory. Unlike forced dilutive financings common in biotech, warrant exercises represent active investor choice, signaling conviction in Nutriband's ability to deliver value.

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting scheduled for Sept. 18. Nutriband emphasized that the NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. If approved, the patch could become the first and only abuse-deterrent transdermal fentanyl product globally, with peak annual sales estimated between $80 million and $200 million. AVERSA Buprenorphine, the company's second program, is projected to reach peak annual sales of up to $130 million. Nutriband continues to grow revenue through its Pocono Pharma contract manufacturing subsidiary, which contributed to the record first half.

To view the full press release, visit https://ibn.fm/spHiy

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Wednesday's trading session at $6, off by 1.3158%, on 114,090 volume. The average volume for the last 3 months is 163,075 and the stock's 52-week low/high is $3.7223/$11.78.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl
• InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma (NASDAQ: LTRN) , an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN's BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company's mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his outlook on the future of precision neuro-oncology.

To view the full press release, visit https://ibn.fm/ITg2o

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Wednesday's trading session at $3.96, off by 2.2222%, on 101,494 volume. The average volume for the last 3 months is 102,057 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

• Lantern Pharma Inc. (NASDAQ: LTRN) - BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN's BioMedWire Podcast 
• BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial 
• MissionIRNewsBreaks - Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development